NCT04069325UnknownNot Applicable
Efficacy and Safety of Simiaowan in Prevention of Acute Flares in Chronic Gout Patients Initiating Febuxostat Therapy：a Randomized Controlled Trial
Guang'anmen Hospital of China Academy of Chinese Medical Sciences1 site in 1 country72 target enrollmentStarted: September 1, 2019Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Enrollment
- 72
- Locations
- 1
- Primary Endpoint
- Proportion of subjects experiencing ≥ 1 gout flare within 12 weeks
Study Overview
Brief Summary
The aim of this study is to evaluate the efficacy and safety of simiaowan in prevention of acute flares in chronic gout patients initiating febuxostat therapy.
Detailed Description
The study is a multicenter, randomized, double-blind, placebo-controlled, 12-week trial. To determine whether oral simiaowan at standard clinical doses (6g twice daily), compared to placebo, can reduce the incidence of acute gout flares and decrease the serum uric acid level.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Triple (Participant, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male or female subjects aged 18 to 75 years (time of get informed consent)
- •Meet the American College of Rheumatology/The European League Against Rheumatism criteria (2015) for the classification of acute arthritis of primary gout
- •Pain Visual Analogue Scale Score (VAS) ≤ 3 at screening
- •Serum uric acid ≥7 mg/dL (420μmol/L) at screening
- •Self-reported history of at least 2 gout flares within 12 months prior to screening
- •Normal electrocardiogram (ECG), or no clinical significant at screening
- •Be capable of understanding and complying with protocol requirements
Exclusion Criteria
- •Occurrence of an acute gout flare ongoing at screening or within 2 weeks prior to screening
- •Known or suspected of secondary hyperuricemia (e.g. due to renal disorder, hematological disorder, drugs, radiotherapy, chemotherapy or organ transplant)
- •Use of colchicine, allopurinol, probenecid, benzbromarone, febuxostat or history of intra-articular steroid injection within 4 weeks prior to screening
- •Use of glucocorticoids, nonsteroidal antiinflammatory drugs (NSAIDs), or cyclooxygenase-2 (COX-2) inhibitors within 1 week prior to screening
- •History of stroke, transient ischemic attack (TIA), acute myocardial infarction (MI), heart failure (NYHA Class II-IV), coronary intervention procedure (including but not limited to angioplasty, stent placement, coronary revascularization) prior to screening
- •History of gastrointestinal (GI) bleeding, peptic ulcer disease prior to screening
- •History of malignancy and/or mental disorder prior to screening
- •Active infection with hepatitis B, hepatitis C, or has aspartate transaminase (AST), alanine aminotransferase (ALT) or gamma-glutamyl transpeptidase (GGT) values ≥1.2 times the upper limit of normal (×ULN) during the screening period
- •Presence of severe renal function impairment, or has serum creatinine (sCr) values ≥1.2 (×ULN) during the screening period
- •History of allergy or intolerance to febuxostat, diclofenac sodium, simiaowan and/or the placebo
- •History of aspirin-induced asthma, or any other form of allergy to aspirin and other NSAIDs
- •Other (non-gout) chronic arthritis, acute inflammatory arthritis, autoimmune diseases with arthritis at screening
- •Being treated with simiaowan at screening
- •Being treated with azathioprine, mercaptopurine, theophylline, cytotoxic agents at screening
- •Diagnosis of drug or alcohol dependence or abuse or any condition requiring chronic daily use of pain medication
- •Pregnant or nursing, or planning to become pregnant or father a child within 3 months after receiving the last dose of study drug
- •Subjects who participated in another clinical study or clinical trial within 3 months prior to screening
- •Any other condition(s) that will compromise the safety of the patient, prevent compliance with the study protocol, or compromise the quality of the clinical study, as judged by the investigator
Arms & Interventions
simiaowan 6g + febuxostat 40mg
Experimental
Intervention: febuxostat (Drug)
simiaowan 6g + febuxostat 40mg
Experimental
Intervention: simiaowan (Drug)
placebo 6g + febuxostat 40mg
Placebo Comparator
Intervention: placebo (Drug)
placebo 6g + febuxostat 40mg
Placebo Comparator
Intervention: febuxostat (Drug)
Outcomes
Primary Outcomes
Proportion of subjects experiencing ≥ 1 gout flare within 12 weeks
Time Frame: Day 1 to Week 12
Proportion of subjects in each group who experiencing at least 1 new gout flare during the 12 weeks study treatment period.
Secondary Outcomes
- The incidence of new gout flares within 12 weeks in the simiaowan group compared to the placebo group(Day 1 to Week 12)
- Proportion of subjects in each group achieving serum uric acid concentration≤ 7 mg/dL (420μmol/L)(Week4, Week 8 and Week 12)
- Proportion of subjects experiencing from ≥ 1 gout flare and ≥ 2 gout flares within 12 weeks(Day 1 to Week 12)
- Mean pain Visual Analogue Scale Score (VAS) associated with gout flares(Day 1 to Week 12)
- Amount of rescue medication taken within 12 weeks(Day 1 to Week 12)
Investigators
Quan Jiang
Director, Devision of Rheumatology
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Study Sites (1)
Loading locations...
Similar Trials
Completed
Early Phase 1
Efficacy & Safety of the Oral Neurokinin-1 Antagonist, Aprepitant, in Combo With Ondansetron & Dexamethasone in Patients Undergoing Auto Peripheral Blood Stem Cell TransplantationNauseaVomitingNCT00314743Washington University School of Medicine48
Completed
Phase 2
Role of SAMITAL® in the Relief of Chemo-radiation (CT-RT) Induced Oral Mucositis in Head and Neck Cancer PatientsHead-and-neck Squamous Cell CarcinomaOral MucositisNCT01941992Istituto Oncologico Veneto IRCCS120
Terminated
Phase 2
Panhematin for Prevention of Acute Attacks of PorphyriaVariegate PorphyriaHereditary CoproporphyriaAcute Intermittent PorphyriaNCT02922413The University of Texas Medical Branch, Galveston13
Completed
Not Applicable
PENELOPE Observational Study: Prophylaxis and Treatment of Arterial and Venous ThromboembolismHematologic NeoplasmMultiple MyelomaLymphomaMyelodysplastic SyndromeAcute LeukemiaNCT01855698Gruppo Italiano Malattie EMatologiche dell'Adulto99
Recruiting
Phase 2
The effect of Sinamaz drops on the prevention of? ?upper respiratory diseases ?among Iranian Hajj Pilgrims.IRCT20210515051305N2Shahed University180